Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells

Oncology Reports

Volumn 17, Issue 5, 2007, Pages 1201-1205

  Mori, Ryutaro ^a,b   Ishikawa, Takashi ^a   Ichikawa, Yasushi ^a   Taniguchi, Koichi ^a   Matsuyama, Ryusei ^a   Ueda, Michio ^a   Fujii, Yoshiro ^a   Endo, Itaru ^a   Togo, Shinji ^a   Danenberg, Peter V ^b   Shimada, Hiroshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biliary tract carcinoma; Gemcitabine; HENT1; Pancreatic adenocarcinoma

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG DERIVATIVE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; MESSENGER RNA; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; RRM1 PROTEIN, HUMAN; SLC29A1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BILIARY TRACT TUMOR; BIOSYNTHESIS; GENETICS; HUMAN; METABOLISM; METHODOLOGY; PANCREAS TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; CELL LINE, TUMOR; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HUMANS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 34548580650     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.5.1201     Document Type: Article

References (19)

1. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
2. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
3. Huang P and Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol 22: 19-25, 1995.
4. Plunkett W, Huang P and Searcy CE: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23: 3-15, 1996. (Pubitemid 26362189)
5. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T and Ueda R: Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95: 753-757, 2004. (Pubitemid 39335096)
6. Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP and Peters GJ: Induction of resistance to 2′,2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin Oncol 22: 35-41, 1995.
7. Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5: 19-33, 2002.
8. Ruiz van Haperen VW, Veerman G, Eriksson S, et al: Development and molecular characterization of a 2′,2′-difluoro-deoxycytidine- resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54: 4138-4143, 1994.
9. Goan YG, Zhou B, Hu E, Mi S and Yen Y: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204-4207, 1999. (Pubitemid 29418726)
10. Van der Wilt CL, Kroep JR, Bergman AM, et al: The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 486: 287-290, 2000. (Pubitemid 32179314)
11. Kroep JR, Loves WJ, van der Wilt CL, et al : Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1: 371-376, 2002.
12. Eriksson S, Gudas LJ, Clift SM, Caras IW, Ullman B and Martin DW Jr: Evidence for genetically independent allosteric regulatory domains of the protein M1 subunit of mouse ribonucleotide reductase. J Biol Chem 256: 10193-10197, 1981. (Pubitemid 12202060)
13. Tanaka H, Arakawa H, Yamaguchi T, et al : A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42-49, 2000. (Pubitemid 30143125)
14. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23: 1539-1548, 2004. (Pubitemid 38406516)
15. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM and Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64: 3761-3766, 2004. (Pubitemid 38697284)
16. Mackey JR, Yao SY, Smith KM, et al: Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91: 1876-1881, 1999.
17. +-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol Membr Biol 18: 65-72, 2001.
18. Mackey JR, Mani RS, Selner M, et al: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357, 1998. (Pubitemid 28450036)
19. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M: Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9: 5000-5008, 2003. (Pubitemid 37323307)